Forxiga

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Nephropathy

Conditions

Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes, Autonomic Neuropathy, Diabetic

Trial Timeline

Feb 1, 2020 → Jan 1, 2021

NCT ID

NCT04193566

About Forxiga

Forxiga is a approved stage product being developed by Novo Nordisk for Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04193566. Target conditions include Nephropathy, Hypoxia, Mitochondrial Alteration.

What happened to similar drugs?

5 of 20 similar drugs in Nephropathy were approved

Approved (5) Terminated (3) Active (12)

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

✅CyclosporineNovartisApproved

✅nisoldipine + lisinoprilBayerApproved

✅Intravenous Rituximab + ACE/ARBBiogenApproved

🔄olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3

❌Rituximab + cyclosporineSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04193566	Approved	Completed	Feb 1, 2020	Jan 1, 2021	Nephropathy

Competing Products

20 competing products in Nephropathy

See all competitors

Product	Company	Stage	Hype Score
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22
Tacrolimus + Placebo	Astellas Pharma	Phase 2	35
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	32
Placebo + LY3016859	Eli Lilly	Phase 1/2	32
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1	Eli Lilly	Pre-clinical	26
HR19042 Capsules + Placebo	Jiangsu Hengrui Medicine	Phase 2	35
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 capsule	Jiangsu Hengrui Medicine	Phase 1	29
Atrasentan + Placebo	AbbVie	Phase 3	32
Atrasentan	AbbVie	Phase 2	35
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
ALXN1920 + Placebo	AstraZeneca	Phase 2	42
Candesartan	AstraZeneca	Pre-clinical	26
Placebo + Atacicept 25 mg + Atacicept 75 mg	Merck	Phase 2	27
BION-1301 + Placebo	Novartis	Phase 3	44
MAU868 + Placebo	Novartis	Phase 2	27
Atrasentan	Novartis	Phase 2	39